• RIPA Lysis Buffer (Strong): Reliable Protein Extraction in R

  2026-07-26

  This article provides an in-depth, scenario-driven analysis of common laboratory challenges in protein extraction from animal tissues and cultured cells, focusing on the robust performance of RIPA Lysis Buffer (Strong), SKU K1020. Drawing on validated protocols and comparative insights, the discussion highlights how this radioimmunoprecipitation assay buffer ensures reproducibility and compatibility for Western blot sample preparation and immunoprecipitation workflows.

• E-64d in Cell Death Pathways: Protocols, Use Cases, and Opti

  2026-07-25

  E-64d, a potent membrane-permeable cysteine protease inhibitor, enables precise dissection of regulated cell death mechanisms and neuroprotection strategies. This guide translates cutting-edge reference findings into actionable protocols and troubleshooting for apoptosis, platelet activation, and lysoptosis research.

• HyperScript III RT SuperMix: Precision cDNA Synthesis for qP

  2026-07-24

  HyperScript III RT SuperMix streamlines the reverse transcription of low-concentration and high-GC content RNA, delivering robust, reproducible cDNA for advanced qPCR workflows. Its integrated gDNA wiper ensures confident gene expression analysis by eliminating genomic DNA contamination—crucial for translational studies like CRC immunogenomics.

• Ionic Regulation of Cancer Cell Stiffness via MRTFA-KCNMB1 A

  2026-07-24

  Gajda et al. uncover how the MRTFA-KCNMB1 signaling axis modulates cancer cell stiffness and metastatic potential through potassium channel regulation. Their work demonstrates that BK channel activation can increase cancer cell rigidity, sensitizing tumors to immune cell-mediated destruction, and reveals new therapeutic angles for metastasis control.

• SU 5402 in Precision Neuronal and Cancer Signaling: Beyond K

  2026-07-23

  Explore how SU 5402 empowers advanced research in cancer biology and neuronal models through precise, multi-pathway kinase inhibition. This article uniquely bridges mechanistic insights with translational assay design, setting it apart from prior coverage.

• CIRT Induces Ferroptosis and M1 Polarization in Gastric Canc

  2026-07-23

  Wang and Cai (2025) demonstrate that carbon-ion radiotherapy (CIRT) inhibits gastric cancer progression by inducing ferroptosis and promoting M1 macrophage polarization through DHODH downregulation. These findings position DHODH as a promising target to enhance CIRT efficacy, offering new mechanistic insight into advanced radiotherapy strategies for gastric tumors.

• Verteporfin: Illuminating New Pathways in Translational Rese

  2026-07-22

  This article examines Verteporfin’s dual mechanisms—light-activated photodynamic therapy and light-independent autophagy inhibition—through the lens of surface ectoderm commitment, regulatory network modulation, and translational research. Drawing from cutting-edge findings on YAP-TEAD’s control of super-enhancer networks, we provide mechanistic insights, protocol guidance, and a perspective on Verteporfin’s role in next-generation regenerative medicine.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Axis

  2026-07-22

  This study uncovers gramine’s novel role in suppressing triple-negative breast cancer (TNBC) by inducing ferroptosis through the CUL3–MTDH axis. The findings provide mechanistic insight into ferroptosis regulation and highlight gramine’s promise as a targeted therapeutic approach for aggressive breast cancers.

• SHC-1 Inhibition Modulates CFTR Membrane Abundance in Epithe

  2026-07-21

  This study elucidates how SHC-1-mediated signaling regulates plasma membrane CFTR abundance across epithelial models, revealing a conserved pathway and highlighting model-specific nuances. The findings refine mechanistic understanding of CFTR trafficking, informing experimental design in cystic fibrosis and secretory diarrhea research.

• JSH-23: Precision NF-κB Inhibitor for Inflammation Research

  2026-07-21

  JSH-23 is a selective NF-κB inhibitor that empowers researchers to dissect inflammatory signaling with unprecedented specificity. Its unique mechanism—blocking p65 nuclear translocation without interfering with IκB degradation—makes it ideal for advanced inflammation models and cytokine regulation studies.

• Ruxolitinib Phosphate: Applied JAK/STAT Modulation in Cancer

  2026-07-20

  Ruxolitinib phosphate (INCB018424) enables precise JAK/STAT pathway inhibition, advancing both autoimmune and cancer model workflows with robust experimental reproducibility. Explore stepwise protocols, troubleshooting strategies, and the latest mechanistic insights—anchored by a landmark study linking JAK/STAT suppression to mitochondrial dynamics in aggressive thyroid cancer.

• Silver Nanoparticles Trigger Liver Ferroptosis in Zebrafish

  2026-07-20

  This study identifies ferroptosis as a key driver of liver inflammation following silver nanoparticle exposure in zebrafish, pinpointing pivotal gene regulators and metabolic disruptions. These findings clarify mechanistic links between nanomaterial toxicity, iron-dependent cell death, and metabolic disease pathways.

• Ruxolitinib (INCB018424): Benchmarks in JAK1/2 Inhibition Re

  2026-07-19

  Ruxolitinib (INCB018424) is a highly selective JAK1/2 inhibitor, widely used to interrogate myeloproliferative disorder mechanisms and immune modulation. This article details its mechanism, performance benchmarks, and best-practice integration in research workflows.

• HRR Gene Expression Predicts PARP Inhibitor Response in MPM

  2026-07-18

  Borchert et al. (2019) demonstrate that gene expression profiling of the homologous recombination repair (HRR) pathway can identify malignant pleural mesothelioma (MPM) subgroups susceptible to PARP inhibitor therapy. Their findings suggest that HRR defects, particularly BAP1 mutations, may guide precision treatment strategies beyond standard chemotherapy.

• FOXM1–ERα ceRNA Networks in Female Lung Adenocarcinoma: Insi

  2026-07-17

  The reference study uncovers a novel FOXM1–estrogen receptor alpha (ERα) competitive endogenous RNA (ceRNA) network driving female lung adenocarcinoma (LUAD) progression. By integrating transcriptomic analyses, molecular validation, and immunotherapy response profiling, the work provides mechanistic and biomarker advances with clear implications for ERα-focused cancer research.

15362 records 1/1025 page Next 12345 下5页 Last page